Search

everythinglearnresearchcommunity

for

Search:↓

Injectable platelet-rich fibrin is better than platelet-rich plasma for promoting hair growth.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Blocking TGFβ-RI signaling enhances surface ectoderm differentiation from human stem cells.

Targeting specific cell interactions may help treat skin fibrosis.

Combining these plant extracts kills mosquito larvae effectively.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Promising cancer treatments were found, but the manufacturer closed.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

The drug combination was safe and showed promise in treating advanced tumors.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Upadacitinib effectively treats pyoderma gangrenosum.

Golvatinib shows promise as a treatment for Omicron in elderly patients.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

The combination treatment showed a higher response rate but no significant survival benefits.